ACTIVE

Investing in companies and technologies that address unmet health and economic needs
ASI Logo - New.png
 
Ablative Solutions, Inc.

Kalamazoo, MI

BioStar II

Ablative Solutions, Inc., located in Kalamazoo, MI, is focused on designing a transcatheter chemo-denervation treatment for the renal nerves to alleviate refractory hypertension.
www.ablativesolutions.com

 
Aria CV, Inc.

St. Paul, MN

BioStar III

Aria CV, Inc. is developing a cardiovascular medical device to treat patients with pulmonary hypertension, or high blood pressure in the arteries of the lungs. Pulmonary hypertension causes increased workload on the heart, eventually leading to right-sided heart failure. Employing a novel mechanism, Aria CV’s device has the potential to improve outcomes by reducing right ventricular workload.

www.ariacv.com

 
Autonomix Medical, Inc.

Ivyland, PA

BioStar III

Autonomix Medical, Inc. was founded in 2014 as a collaboration between BioStar Ventures and a world-renowned group of cardiologists and engineers. The company is developing novel electrophysiologic technology for human autonomic neural sensing with multiple possible clinical applications. One purpose is to determine optimal patient selection for successful renal denervation and to intra-procedurally detect denervation efficacy in real time.

www.autonomixmed.com

CathWorks Ltd.

Kfar Saba, Israel

BioStar III

CathWorks Ltd. is developing an image-based fractional flow reserve (FFR) measurement designed to replace the pressure wire-based, drug-induced measurement currently performed. The CathWorks angiogram-based FFR (FFRangio) technology provides a less-invasive assessment tool to improve real-time functional assessment that guides treatment decisions and to make coronary catheterization procedures safer, shorter, more accurate, and more comprehensive.

www.cath.works

cathworks_logo-01.jpg
 
 
Corindus Vascular Robotics, Inc. (NYSE: CVRS)

Waltham, MA

BioStar III

Corindus Vascular Robotics, Inc. (NYSE: CVRS) is a global technology leader in robotic-assisted vascular interventions. The company's FDA-cleared CorPath System brings robotic precision to radial, coronary, and peripheral procedures to optimize clinical outcomes and minimize costs associated with complications during manual procedures.

www.corindus.com

Foldax, Inc.

Salt Lake City, UT

BioStar III

Foldax, Inc. is developing synthetic heart valves with the goal of delivering non-thrombogenic aortic and mitral valves at dramatically lower costs versus existing artificial and tissue valves.

www.foldax.com

 
 
NewPace Ltd.

Caesarea, Israel

BioStar III

NewPace Ltd. is an Israeli medical device company developing breakthrough, out-of-the-box solutions for the cardiac rhythm management space.

www.newpacemedical.com

 
TransMedics Group, Inc. (NASDAQ: TMDX)

Andover, MA

BioStar III

TransMedics, Inc. (NASDAQ: TMDX) is the world’s leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation, and has developed technologies to improve organ quality, validate organ viability, and increase the utilization of transplant organs for the treatment of end-stage heart, lung, and liver failure.

www.transmedics.com

 
Trice Medical, Inc.

King of Prussia, PA

BioStar II, BioStar III

Trice Medical, Inc., located in King of Prussia, PA, is a private diagnostics company focused on micro-invasive technologies and has pioneered fully-integrated, camera-enabled needle technologies that provide a clinical solution that is optimized for the physician’s office.

www.tricemedical.com

Trice Logo - New.png
V-Wave Ltd.

Caesarea, Israel

BioStar III

V-Wave Ltd. is developing a proprietary unidirectional inter-atrial shunt for the treatment of heart failure. The percutaneous implantable device, which regulates left atrial pressure, is designed to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve overall quality of life.

www.vwavemedical.com

 
 
Vytronus, Inc.

Sunnyvale, CA

BioStar III

Vytronus, Inc. was founded to harness the elegant imaging and therapeutic capabilities of ultrasound energy to treat cardiac arrhythmias, starting with atrial fibrillation. The company is developing a catheter-based endocardial ablation platform based on Low-Intensity Collimated Ultrasound (LICU™). LICU is capable of quickly producing high-resolution maps of cardiac anatomy and allows for non-contact energy delivery to create durable continuous linear lesions. The Vytronus system is designed to enable physicians to treat complex arrhythmias with better flexibility, control, and ease of use.

www.vytronus.com

Vytronus - New.png